FIELD: pharmacology.
SUBSTANCE: method for skin tumor treatment by TNF immunoconjugate single dose injectionα and IL-2 immunoconjugate single dose to tumor localization site, at that, injectable administration of TNF immunoconjugateα and IL-2 immunoconjugate is carried out simultaneously. TNF immunoconjugateα contains TNFα, bound to an antibody molecule that binds to the additional ED-B domain of the B-FN fibronectin splice isoform. The IL-2 immunoconjugate comprises IL-2, bound to an antibody molecule that binds to the additional ED-B domain of the B-FN fibronectin splice isoform. The invention also relates to compositions for skin tumor treatment comprising the said TNF immunoconjugateα and/or the said IL-2 immunoconjugate.
EFFECT: invention provides for stimulation of complete destruction of large subcutaneous tumors with a single local administration of a combination of TNF immunoconjugateα and IL-2 immunoconjugate.
42 cl, 4 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| IL-12 COMPOSITIONS AIMED AT EDB | 2019 |
|
RU2758143C1 |
| COMBINATION OF ANTI-EDb FIBRONECTIN ANTIBODY-IL-2 FUSION PROTEIN, AND MOLECULE BINDING TO B-CELLS, B-CELL PROGENITORS AND/OR THEIR CANCEROUS COUNTERPART | 2008 |
|
RU2484845C2 |
| ANTIGEN ASSOCIATED WITH RHEUMATOID ARTHRITIS | 2013 |
|
RU2649368C2 |
| ANTIGENS ASSOCIATED WITH INFLAMMATORY BOWEL DISEASE | 2012 |
|
RU2612878C2 |
| IL2 AND MUTANT TNF IMMUNOCONJUGATES | 2017 |
|
RU2758139C2 |
| IMMUNOCONJUGATES OF DIRECTIVE EFFECT | 2010 |
|
RU2583876C2 |
| COMBINED THERAPY BASED ON TUMOUR-TARGETED IMMUNOCYTOKINES CONTAINING VARIANT IL-2, AND ANTIBODIES TO HUMAN PD-L1 | 2015 |
|
RU2710354C2 |
| MYOCARDIAL INFARCTION TREATMENT USING TGF-BETA ANTAGONISTS | 2011 |
|
RU2637088C2 |
| STRUCTURED ANTI-TGF-BETA ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS | 2014 |
|
RU2681502C2 |
| RECOMBINANT IMMUNOTOXIN AIMED AT MESOTHELIN | 2012 |
|
RU2600067C2 |
